BioSpecifics Technologies Corp. is a profitable, commercial-stage biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is approved for marketing as XIAFLEX® in the U.S. for the treatment of adult Dupuytren's contracture patients with up to two palpable cords in the same palm and for Peyronie's disease in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy. XIAFLEX® is marketed in Japan for Dupuytren's contracture and XIAPEX (the EU tradename) is marketed in the EU for both Dupuytren's contracture and Peyronie's disease. XIAFLEX® is also approved in Canada and Australia for Dupuytren's contracture.

BioSpecifics' strategic partner, Endo International plc (Endo), markets XIAFLEX® for Dupuytren's contracture and Peyronie's disease in the U.S. and is also managing the research and development of XIAFLEX® for their licensed indications, which include frozen shoulder syndrome, cellulite, lateral thigh fat, plantar fibromatosis and canine lipoma. Ex-U.S partnerships include Actelion Pharmaceuticals Ltd. in Canada, Australia, Brazil and Mexico, Asahi Kasei Pharma Corporation in Japan and Swedish Orphan Biovitrum AB in 71 Eurasian and African countries.

BioSpecifics is currently managing the clinical development of XIAFLEX® for the treatment of human lipoma and preclinical development of uterine fibroids.

Patient Discussion Forums

Forums are designed to enable patients and others concerned to interact with each other. Discussions on virtually any aspect of lipoma and Peyronie's disease are acceptable, however, please abide by the guidelines.